688139 海尔生物
2026/03 - 三个月
(K)
2025/12
(K)
2024/12
(K)
2023/12
(K)
2022/12
(K)
经营活动产生之现金流量净额11,677267,894291,667249,265632,429
投资活动产生之现金流量净额243,54016,745(791,217)252,756(251,175)
筹资活动产生之现金流量净额(1,633)(268,736)(226,827)(168,299)(206,234)
汇率变动对现金及现金等价物的影响(7,435)3,2004,435(8,238)8,899
现金及现金等价物净增加/(减少)246,14919,103(721,943)325,483183,919
期初现金及现金等价物余额553,807534,7041,256,647931,164747,245
期末现金及现金等价物余额799,956553,807534,7041,256,647931,164